CJC-1295 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Possible water retention, tingling/numbness in hands (carpal tunnel-like), increased appetite, mild headache, and flushing at injection site. Effects are dose-dependent and typically subside with continued use. CJC-1295 is not fda-approved. research chemical status. banned by wada. As with any research compound, individual responses vary.
Is CJC-1295 Safe?
Safety is the most important consideration with any research compound. CJC-1295 (CJC-1295 (Modified GRF 1-29)) is a Growth Hormone Releasing Hormone (GHRH) analog with a safety profile established through preclinical research.
Clinical research demonstrates significant increases in GH and IGF-1 levels in human subjects. Studies show improved body composition with increased lean mass and reduced body fat, particularly when combined with GHRP peptides like Ipamorelin.
What Are the Known Side Effects of CJC-1295?
Possible water retention, tingling/numbness in hands (carpal tunnel-like), increased appetite, mild headache, and flushing at injection site. Effects are dose-dependent and typically subside with continued use.
These effects are based on preclinical data and community reports at standard dosages of 100-300 mcg. Higher doses generally increase both the likelihood and severity of side effects.
Are CJC-1295 Side Effects Dose-Dependent?
Most reported CJC-1295 side effects are dose-dependent — meaning they're more likely at higher doses and less likely at the lower end of the 100-300 mcg range.
This is why starting at the minimum effective dose and titrating up is the standard approach. With a half-life of ~30 minutes (no DAC), ~8 days (with DAC), any adverse effects will typically resolve within a few half-life periods after discontinuation.
What About Long-Term CJC-1295 Use?
Long-term safety data for CJC-1295 is limited, as with most research peptides. Standard cycles run 8-12 weeks, often paired with Ipamorelin.
CJC-1295 is not fda-approved. research chemical status. banned by wada. Extended use beyond recommended cycles should be approached with caution.
Does CJC-1295 Interact With Other Compounds?
The gold standard stack is CJC-1295 + Ipamorelin — GHRH + GHRP together produce GH pulses far greater than either alone, through synergistic pituitary stimulation via two distinct receptor pathways.
When stacking peptides, be aware that combining multiple compounds increases the total side-effect surface area. Monitor closely when introducing any new compound.
How Can You Minimize CJC-1295 Side Effects?
Start at the lower end of the dosage range (100-300 mcg). Use proper reconstitution and injection technique to minimize injection site reactions. Store correctly (lyophilized at -20°C, reconstituted at 2-8°C) to maintain purity.
Source only from vendors with third-party COA testing — contaminated or mislabeled products are a significant source of unexpected adverse effects.
What Is the Bottom Line on CJC-1295 Safety?
Possible water retention, tingling/numbness in hands (carpal tunnel-like), increased appetite, mild headache, and flushing at injection site. Effects are dose-dependent and typically subside with continued use. Overall, CJC-1295 is considered a compound requiring careful monitoring at standard research doses.
Read our CJC-1295 dosage guide for protocols designed to minimize risk.
Complete Guide
CJC-1295 : Benefits, Dosage, Side Effects & Research
Related Reading
- CJC-1295 Dosage Guide
- CJC-1295 Benefits
- CJC-1295 Stacking Guide
- CJC-1295 Cycle Guide
- CJC-1295 Research
- Ipamorelin Complete Guide
Calculate Your CJC-1295 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for CJC-1295.
Open Calculator →Research-Grade Sourcing
If you're going to research CJC-1295, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 (CJC-1295 (Modified GRF 1-29)) is a Growth Hormone Releasing Hormone (GHRH) analog. Synthetic peptide analog of GHRH (first 29 amino acids) with four amino acid substitutions for enhanced stability. It is researched for increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects.
What is the recommended CJC-1295 dosage?
Common dosages: 100-300 mcg administered 1-3 times daily, typically before bed via subcutaneous injection. Cycle length: 8-12 weeks, often paired with Ipamorelin. Half-life: ~30 minutes (no DAC), ~8 days (with DAC). Use our peptide calculator for exact reconstitution math.
What are the side effects of CJC-1295?
Possible water retention, tingling/numbness in hands (carpal tunnel-like), increased appetite, mild headache, and flushing at injection site. Effects are dose-dependent and typically subside with continued use.
Is CJC-1295 safe?
CJC-1295 has shown a preliminary safety profile in research. Not FDA-approved. Research chemical status. Banned by WADA. All research should follow appropriate safety protocols.